Sign in Subscribe
Coronaviruses

BioNTech Aims to Develop mRNA Vaccine Against Malaria

Strategic Insights

— 1 min read

Pharmaceutical company BioNTech is working on a new vaccine to target malaria, leveraging the mRNA technology behind its successful coronavirus vaccine. The company plans to start clinical trials for a "safe and highly effective malaria vaccine" by the end of next year. In addition to developing a malaria vaccine, BioNTech is also seeking to establish an mRNA vaccine production facility in Africa, which has struggled to obtain sufficient supplies of COVID-19 vaccine doses. This initiative aims to evaluate and establish sustainable mRNA manufacturing capabilities on the African continent to supply African countries with vaccines.

Key Takeaways:

  • BioNTech plans to use the mRNA technology behind its coronavirus vaccine to target malaria, with clinical trials scheduled to begin by the end of next year.
  • The company aims to develop a "safe and highly effective malaria vaccine" to combat the disease.
  • BioNTech is seeking to establish an mRNA vaccine production facility in Africa to supply African countries with vaccines.
  • The facility will be able to manufacture various mRNA-based vaccines once built.
  • BioNTech and Pfizer have committed to delivering 1 billion doses of their COVID-19 vaccine to middle-and low-income countries in 2022.
  • The company is working with partners to develop the manufacturing capabilities on the African continent.
  • BioNTech has previously mentioned working on a vaccine candidate for tuberculosis, with clinical trials aimed for 2022, and therapies for several forms of cancer.

Statistics:

  • BioNTech plans to start clinical trials for a malaria vaccine by the end of next year.
  • The company aims to deliver 1 billion doses of its COVID-19 vaccine to middle-and low-income countries in 2022.
  • 1 billion doses of the COVID-19 vaccine will be delivered to middle-and low-income countries in 2022, in addition to the 1 billion doses this year.

Sources:

Source 1 - AP News Wire

Source 2 - BioNTech's official statement

Source 3 - Pfizer's official statement

Read more